Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
08:00am, Tuesday, 03'rd Jun 2025
NORTH CHICAGO, Ill. , June 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025.
Put Cash To Work: 2 Magnificent Dividends I'm Betting On
10:00am, Monday, 02'nd Jun 2025
High-quality assets like RTX and AbbVie are ideal for growth and income, offering inflation resilience and strong shareholder returns. RTX has a robust $217B backlog, rising global defense spending, r
Final Trades: JPMorgan, Meta, Abbvie and Gap
04:20pm, Friday, 30'th May 2025
The Investment Committee give you their top stocks to watch for the second half.
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join – Contact Levi & Korsinsky
12:38pm, Friday, 30'th May 2025
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a cl
AbbVie Partners with Chicago Cubs on "Striking Out Cancer"
08:00am, Friday, 30'th May 2025
Chicago-based institutions aim to create greater awareness for cancer advocacy and to support non-profit cancer organizations NORTH CHICAGO, Ill. , May 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) ann
NEW YORK , May 30, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class
Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc.(ABBV)
12:22pm, Thursday, 29'th May 2025
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
AbbVie Stock Down Around 13% in 3 Months: Time to Buy the Dip?
10:36am, Thursday, 29'th May 2025
ABBV drops 12.6% in three months, but rising Skyrizi and Rinvoq sales, pipeline strength, and 2025 growth outlook support staying invested.
When $7 Trillion Wakes Up: Buy These 3 Dividend Stocks Before Everyone Else Does
07:30am, Thursday, 29'th May 2025
Money market funds are booming with $7.2 trillion in assets, offering attractive short-term yields, but rising fees and competition could shake things up. I believe we're nearing a turning point: lowe
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm
05:45am, Thursday, 29'th May 2025
NEW YORK , May 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV du
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
10:06am, Wednesday, 28'th May 2025
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Best Dividend Aristocrats For June 2025
10:15pm, Tuesday, 27'th May 2025
Dividend Aristocrats have slightly outperformed the S&P 500 year-to-date, despite underperforming in April and May. Dividend growth remains robust, with 41 of 69 Aristocrats announcing increases in 20
Lost Money on Cerevel Therapeutics Holdings, Inc. (ABBV)? Urged to Join Class Action Before June 3, 2025 - Contact Levi & Korsinsky
09:15am, Tuesday, 27'th May 2025
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal
- Key oral presentations highlight new data from AbbVie's novel investigational antibody-drug conjugates (ADCs) including telisotuzumab adizutecan (ABBV-400, Temab-A) in advanced non-small cell l
Levi & Korsinsky Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ABBV
07:30am, Tuesday, 27'th May 2025
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal
